Shengqing Jiangzhuo Capsule Alleviates Intestinal Inflammation in Chronic Kidney Disease by Downregulating CHAC1 to Inactivate the HIF-1 Pathway.

ABSTRACT:

Background

Chronic kidney disease (CKD) imposes significant global health burdens. Shengqing Jiangzhuo (SQJZ) capsule possesses potential to alleviate CKD via gut-kidney axis, with the specific role and mechanisms involving CHAC glutathione-specific γ-glutamylcyclotransferase 1 (CHAC1) and hypoxia-inducible factor 1 (HIF-1) signaling remaining unclear.

Methods

Adenine-induced CKD rats were treated with SQJZ capsule for 4 weeks. The levels of blood urea nitrogen (BUN), serum creatinine (SCR), urine albumin/creatinine ratio (ACR), and inflammatory markers in colon tissues, including proinflammatory cytokines and oxidative markers, were assessed via enzyme-linked immunosorbent assay (ELISA). The renal pathology was estimated by histopathology. Transcriptomic sequencing combined

SUBMITTER: Li Z 

PROVIDER: S-EPMC12615044 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature